Monoclonal antibodies (mAbs) against mucin 21 (MUC21), a human counterpart of mouse epiglycanin/ Muc21, were prepared using human embryonic kidney 293 cells transfected with MUC21 as the immunogen. The specificity of these mAbs was examined by flow cytometry, immunoprecipitation and western blotting focusing on the differential glycosylation of MUC21 expressed in variant Chinese hamster ovary (CHO) cells (ldlD cells and Lec2 cells) and CHO-K1 cells. One of these mAbs, heM21D, bound to both the unmodified core polypeptide of MUC21 and MUC21 attached with N-acetylgalactosamine (Tn-MUC21). Six antibodies, including mAb heM21C, bound to MUC21 with Tn, T or sialyl-T epitopes but not the unmodified core polypeptide of MUC21. Esophageal squamous carcinomas and adjacent squamous epithelia were immunohistochemically examined for the binding of these mAbs. MUC21 was expressed in esophageal squamous epithelial cells, and its O-glycan extended forms were observed in the luminal portions of squamous epithelia. As revealed by the binding of mAb heM21D and the absence of reactivity with mAb heM21C, esophageal squamous carcinoma cells produce MUC21 without the attachment of O-glycans. This is the first report to show that there is a change in the glycoform of MUC21 that can be used to differentiate between squamous epithelia and squamous carcinoma of the esophagus. Thus, these antibodies represent a useful tool to characterize squamous epithelial differentiation and carcinogenesis.
Introduction
Mucins are highly glycosylated glycoproteins that are expressed by many epithelial cells and carcinoma cells. Secreted and membrane-bound mucins serve to protect and lubricate epithelial surfaces. Carcinoma-associated mucins are used as tissue and serum markers of breast, ovarian and other cancers. Overproduction, aberrant glycosylation and changes in the secretion patterns of mucins have provided the basis (Hollingsworth and Swanson 2004) for the use of serum detection of MUC1 (CA15-3) and MUC16 (CA125) to monitor the presence and disease activity of malignant tumors (Yarbro et al. 1999; Sturgeon et al. 2008) .
Epiglycanin was discovered as a cell surface, rod-shaped glycoprotein expressed by a subset of TA3 mouse mammary carcinoma cells isolated from a spontaneous tumor in A/HeHa mice (Codington et al. 1972) . A comparison of two ascites forms, TA3-Ha and TA3-St, which were separately maintained, revealed that TA3-Ha cells grew in an allogeneic mouse and showed aggressive behavior, whereas TA3-St cells grew only in a syngeneic mouse (Klein 1951; Codington et al. 1972 Codington et al. , 1975 . Because epiglycanin was present on TA3-Ha cells, but not on TA3-St cells, this molecule was proposed to be responsible for the properties of TA3-Ha cells (Hauschka et al. 1971; Codington et al. 1978) . This hypothesis remained untested until the molecular structure of the gene was identified. The putative epiglycanin gene was identified by the representational difference analysis method and termed as mouse mucin 21 (Muc21), according to the order of the discovery of the human counterpart of this mucin (Itoh et al. 2008) . The biological properties of cells expressing Muc21 have been the subject of extensive investigation in our group, and we previously reported that the overexpression of this mucin made cells non-adherent by interfering with integrin functions (Yi et al. 2010) . Because this property of mouse Muc21 was dependent on the presence of a highly glycosylated extracellular domain, we hypothesized that the glycoform could be involved in the regulation of its biological properties (Yi et al. 2010) .
The human counterpart of this mucin was identified by homology search and termed MUC21 (Itoh et al. 2008 ). The MUC21 gene was located in the major histocompatibility gene complex and was recently reported to be a member of the small mucin gene cluster located within the susceptibility locus for diffuse panbronchiolitis (Hijikata et al. 2011 ).
The expression of MUC21 cDNA resulted in a mucin consisting of a cytoplasmic tail, a transmembrane domain, a stem domain and 28 tandem repeats of 15 amino acids that are composed of nearly 60% serine and threonine residues (Itoh et al. 2008 ). In our previous work, we prepared polyclonal antisera against the cytoplasmic tail of MUC21 (anti-MUC21 CT antisera) in rabbits, and the expression of MUC21 in lung tissues was examined. However, the relevant glycoforms of MUC21 in normal and malignant tissue remain unclear.
In the present study, we generated seven hybridoma clones, which produce monoclonal antibodies (mAbs) specific for the extracellular domain of MUC21, using human embryonic kidney (HEK) 293 cells transfected with MUC21 as an immunogen. These mAbs bound MUC21 in a glycoform-dependent manner, as revealed by flow cytometric and western blotting analyses of MUC21 produced by glycosylation variants of Chinese hamster ovary (CHO) cells. Furthermore, the immunohistochemical binding profiles of two antibodies, an antibody shown to react with non-glycosylated MUC21 and MUC21 with attached N-acetylgalactosamine (GalNAc) residues and an antibody that reacts with MUC21 containing extended O-glycans or GalNAc residues, were examined in esophageal squamous carcinoma and adjacent normal tissue specimens. These results demonstrated that O-glycan extension in esophageal squamous epithelial cells was only located at the luminal side. However, all of the esophageal squamous carcinoma cells in the surgical specimens tested expressed MUC21 without O-glycans. These results demonstrate that the biological properties and clinical relevance of MUC21 are likely to depend on its glycoforms.
Results

Preparation of anti-MUC21 mAbs
We aimed to prepare mAbs specific for different glycoforms of the extracellular domain of MUC21. HEK293 cells, transfected with MUC21 cDNA, were used as the immunogen. After repeated immunizations, the titer of anti-MUC21 antibodies increased in the sera of immunized mice, as determined by enzyme-linked immunosorbent assay (ELISA) with purified N-FLAG-MUC21-C-myc ( Figure 1A ). Splenocytes from mice were fused with mouse myeloma cells, PAI, and the hybridoma culture supernatants were screened by ELISA using K562 cells transfected with N-FLAG-MUC21 and purified N-FLAG-MUC21-C-myc from HEK293 cells as antigens (see Materials and methods). Positive hybridoma cultures were subjected to cloning by limiting dilution, and seven clones that produced mAbs specific for human MUC21 were chosen and designated as heM21A-G. The isotype of mAb heM21A was IgG2b, while the isotype of all other mAbs was IgG1 (data not shown).
Binding of mAbs heM21A-G to human MUC21 expressed in HEK293 cells The binding of mAb heM21A-G to MUC21 were confirmed by flow cytometric analysis using HEK293 cells transfected with N-FLAG-MUC21-C-myc ( Figure 1B ). The lysates from these cells were also used in western blotting analysis ( Figure 1C ). mAbs heM21A, B, C, E, F and G showed very similar profiles and the profile with mAb heM21D was unique as shown in Figure 1C in which results with mAbs heM21C and heM21D are shown. Both the anti-FLAG mAb 
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and mAb heM21D bound two major bands with molecular masses of 160-and 210-kDa, whereas mAbs heM21C bound only the 210-kDa component of the MUC21 gene product. Additionally, Vicia villosa agglutinin isolectin B4 (VVA-B4), which is specific for GalNAc residues attached to peptides, bound the 210-kDa form, but not the 160-kDa form of MUC21, indicating that the 160-kDa component is the nonglycosylated MUC21 polypeptide. These results suggest that mAb heM21D and mAb heM21C recognize different glycoforms of MUC21.
Characterization of the epitope recognized by mAbs heM21C and heM21D To further characterize which glycoforms of MUC21 are recognized by mAbs heM21C and heM21D, variants of CHO cells, ldlD (Kingsley et al. 1986 ), Lec2 (Altschuler et al. 2000) and CHO-K1 cell lines, were stably transfected with N-FLAG-MUC21. The ldlD cell line has a defect in the formation of UDP-GalNAc; thereby O-glycosylation through the attachment of GalNAc residues to polypeptides does not take place. This pathway can be rescued by supplementing the culture media with GalNAc, although further extension of O-glycans requires the addition of galactose to the media (Kingsley et al. 1986; Wertz et al. 1989) . Thus, the glycoforms of mucins produced by this cell line in the absence and the presence of GalNAc are assumed to be those shown in Figure 2A and B, if core 1 is the dominant form of extension. The Lec2 cell line lacks the CMP-sialic acid transporter (Altschuler et al. 2000) . Because Lec2 cells cannot translocate CMP-sialic acid to the lumen of the Golgi apparatus, sialylated epitopes, such as sialyl-T-antigen, are not synthesized in these cells ( Figure 2C ). Wild-type CHO-K1 cells transfected with N-FLAG-MUC21 are expected to express sialyl-T-antigen ( Figure 2D ). Clones were obtained from the transfected cells using the limiting dilution technique, and a clone with high levels of anti-FLAG mAb binding was chosen from each recipient. The glycoforms in Figure 2 are confirmed as described below, except that MUC21 synthesized by Lec2 cells contained glycofroms A and B in addition to C (see below).
We performed flow cytometric analyses of these MUC21 transfectants. Anti-FLAG mAb and mAb heM21D bound to ldlD cells transfected with N-FLAG-MUC21, but not to mock-transfected cells ( Figure 3A ). The binding of mAbs heM21C to ldlD cells transfected with N-FLAG-MUC21 was almost equal to that of mock-transfected cells. Importantly, when ldlD cells transfected with N-FLAG-MUC21 were cultured in media containing GalNAc, both mAb heM21C and heM21D bound to the cells ( Figure 3B ). mAb heM21C and heM21D also bound Lec2 cells transfected with N-FLAG-MUC21 ( Figure 3C ). Interestingly, the binding of mAb heM21D to CHO cells transfected with N-FLAG-MUC21 was significantly weaker than that of other antibodies ( Figure 3D ). These results suggest that mAb heM21D binds to the non-glycosylated core peptide of MUC21, while mAb heM21C bind to glycosylated MUC21. The binding of mAb heM21D seemed to be hindered by the presence of extended carbohydrate chains. Requirement of the polypeptide sequence for the epitope was tested by comparing bindings of these mAbs to Lec2 cells and CHO-K1 cells tranfected with human MUC21 and mouse Muc21. No binding to cells transfected with mouse Muc21 was observed as shown in Figure 3E and F.
To further confirm the specificities of these antibodies, we performed western blotting analyses on the cell lysates. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on 6% polyacrylamide gels, and anti-FLAG mAb, mAb heM21C and mAb heM21D were tested for their binding to the separated components. Blottings with VVA-B4 and peanut agglutinin (PNA), specific for T antigen, were performed after electrophoretic separation of the immunoprecipitants with the anti-FLAG mAb. The anti-FLAG mAb bound to a 160-kDa component derived from ldlD cells transfected with N-FLAG-MUC21 and both 160-and 200-kDa components from the same cells cultured with GalNAc ( Figure 4A ). VVA-B4, specific for Tn antigens, bound specifically to the 200-kDa component but not 160-kDa component, confirming that the 160-kDa component is the core polypeptide of MUC21 and the 200-kDa component corresponds to MUC21 with attached GalNAc residues (Tn-MUC21), as explained in Figure 2 . The mAb heM21C bound the 200-kDa component, whereas mAb heM21D bound both the 160-kDa and 200-kDa components. These results indicate that mAb heM21D selectively binds the unmodified core polypeptides of MUC21 and Tn-MUC21 and that mAb heM21C binds Tn-MUC21 but does not bind the non-glycosylated core polypeptide of MUC21. As shown in Figure 4B , Lec2 cells transfected with N-FLAG-MUC21 synthesized a 160-kDa component and another component migrating above the 200-kDa marker (from the results of staining with anti-FLAG mAb). mAb heM21C bound this >200-kDa component, whereas mAb heM21D bound both the 160-kDa and >200-kDa components. Both VVA-B4 and PNA, bound the >200-kDa components but did not the 160-kDa component suggesting that the >200-kDa components, reactive with mAb heM21C and with mAb heM21D, contained Tn-MUC21 and T-MUC21. Next, lysates of sialidase-treated or untreated CHO-K1 cells transfected with N-FLAG-MUC21 or mock transfectants were subjected to western blotting analysis with these mAbs. Blotting with anti-FLAG mAb revealed a 200-kDa component, whose electrophoretic migration was slower after sialidase treatment. A component with an apparent migration position corresponding to 160 kDa was detected by the anti-FLAG mAb but its relative intensity was low ( Figure 4C ). mAb heM21C bound 200-kDa and >200-kDa component before or after treatment with sialidase ( Figure 4C ). VVA-B4 and PNA were also applied after immunoprecipitation with the anti-FLAG mAb ( Figure 4C ). The binding of PNA to the >200-kDa component was observed in samples from sialidase-treated, but not untreated, CHO-K1 cells transfected with N-FLAG-MUC21. These results indicate that CHO-K1 cells transfected with N-FLAG-MUC21 express sialyl-T-MUC21, and sialidase treatment effectively removed sialic acid from the cells. Binding of VVA-B4 was not detectable with the immunoprecipitated lysates from CHO-K1 cells transfected with N-FLAG-MUC21, untreated or sialidasetreated, indicating that these cells synthesize very low levels of Tn-MUC21 or sialyl-Tn-MUC21. No change was observed in the band intensity of mAb heM21C following sialidase treatment, indicating that the binding of this antibody was not hindered in the presence of sialic acid in O-glycans ( Figure 4C ). mAb heM21D did not bind CHO-K1 cells transfected with N-FLAG-MUC21 regardless of sialidase treatment. Therefore, mAb heM21D does not bind MUC21 with sialyl-T antigen or T antigen. As mentioned above, the >200-kDa components of Lec2 cells contain Tn-MUC21 allowing mAb heM21D to binds, whereas the >200-kDa components of CHO-K1 cells do not. The difference is likely to be due to their differential intrinsic abilities to extend O-glycans in addition to sialylation.
Immunohistological staining of esophageal squamous carcinoma and adjacent normal epithelia Sections from eight cases of esophageal carcinoma were examined with mAb heM21C and mAb heM21D ( Figure 5 ). Both mAb, heM21C and mAb heM21D showed reactivity to the morphologically normal epithelium adjacent to esophageal squamous carcinomas. However, the reactivity of mAb Cell lysates separated by SDS-PAGE on 6% polyacrylamide gels. Immunoprecipitation was performed using agarose beads conjugated with the anti-FLAG mAb. The precipitates were separated by SDS-PAGE and the blotted membranes were incubated with biotinylated VVA-B4, as described in Materials and Methods. (B) Mock-transfected Lec2 cells (M) or Lec2 cells transfected with N-FLAG-MUC21 (T) were grown in a 1:1 mixture of Dulbecco's modified minimum essential medium and Ham F-12 medium. These cells were lysed and processed for SDS-PAGE analysis or subjected to immunoprecipitation. These lysates were subjected to SDS-PAGE and western blotting analyses with mAbs hem21C and heM21D. Aliquots of the lysates were also processed for immunoprecipitation with anti-FLAG mAb, SDS-PAGE and blotting with PNA or VVA-B4. (C) Mock-transfected CHO-K1 cells (M) or CHO-K1 cells transfected with N-FLAG-MUC21 (T) were untreated or treated with sialidase and the lysates were subjected to SDS-PAGE and western blotting analyses with mAbs hem21C and heM21D. Aliquots of the lysates were also processed for immunoprecipitation with anti-FLAG mAb, SDS-PAGE and blotting with PNA or VVA-B4. heM21C was limited to the suprabasal cells, whereas mAb heM21D reacted with the suprabasal, basal and parabasal cells. Esophageal squamous carcinoma cells stained positive for mAb heM21D, but not with mAb heM21C in all eight cases. These results indicate that the glycoform of MUC21 produced by esophageal squamous carcinoma is similar to that present on basal and parabasal squamous epithelia of the esophagus. When these tissues were stained with VVA-B4, the binding was limited to suprabasal cells of esophageal epithelia and the area coincided with the area reactive with both mAbs heM21C and heM21D. Therefore, it is highly likely that Tn epitope on MUC21 is present in suprabasal cells but absent in basal and parabasal cells and in carcinoma cells. It has been suggested that basal cells of esophageal epithelium constitute the stem-cell compartment, and suprabasal cells are undergoing terminal differentiation (Seery and Watt 2000) . Therefore, O-glycosylation and extension of the carbohydrate chain of MUC21 is apparently associated with the differentiation of squamous epithelial cells. Furthermore, it is likely that MUC21 is not attached by O-glycans when expressed by esophageal squamous carcinoma cells.
Discussion
In the present study, we produced antibodies, mAb heM21A-G, which are specific for the extracellular domain of MUC21. Flow cytometric and western blotting analyses with ldlD, Lec2 and CHO-K1 cells stably transfected with N-FLAG-MUC21 clearly indicated that mAb heM21D bound the non-glycosylated core polypeptides of MUC21 and Tn-MUC21, whereas the other antibodies, represented by mAb heM21C, bound Tn-MUC21, T-MUC21 and sialy-T-MUC21. The results also demonstrated that the unmodified core polypeptides of MUC21 were displayed on the surface of the transfectants. Lectin blotting analyses showed that a 160-kDa form of MUC21 was the non-glycosylated core polypeptide and the molecules at 200 and at >200 kDa were glycosylated MUC21 and the results of western blotting analysis with mAb heM21C and mAb heM21D correspond. The amino acid sequence and carbohydrate epitopes of MUC21 recognized by mAbs heM21A-G are still unclear.
Immunohistochemistry with mAb heM21C and mAb heM21D indicated that MUC21 was present in the esophageal epithelium. mAb heM21D bound to basal, parabasal and suprabasal cells, whereas mAb heM21C did not bind to basal and parabasal cells. Furthermore, mAb heM21C did not bind to esophageal squamous carcinomas. These data suggest that suprabasal cells of the esophageal epithelium express MUC21 with Tn epitope and potentially with extended carbohydrate chains. Similar glycoforms of MUC21 do not seem to be present in the basal/parabasal epithelia of esophagus or esophageal squamous carcinoma cells because they do not react with mAb heM21C. It remains possible that the absence of epitope of mAb heM21C in basal/parabasal epithelia and carcinoma cells is due to other changes such as the deletion of the epitope by alternative splicing. However, differential glycosylation is the most likely cause of differential staining with mAb heM21C and heM21D.
Carbohydrate epitopes on mucins are widely used as tumor markers and considered to be essential in monitoring recurrence and tumor burden. The initiation of mucin-type O-glycosylation is regulated by a family of UDP-GalNAc/polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts; Wandall et al. 1997) and there are at least 24 unique ppGalNAc-T human genes (Ten Hagen et al. 2003) . Aberrant expression of ppGalNAc-T isoforms results in aberrant O-glycosylation, which occurs during cancer progression (Hollingsworth and Swanson 2004) . It has been reported that the expression of ppGalNAc-T1 decreases ovarian cancer risk (Phelan et al. 2010) , and ppGalNAc-T3 and T6 are highly expressed in well to moderately differentiated pancreatic cancer, while their expression was low in ductal epithelium or poorly differentiated cancer (Altschuler et al. 2000) . Previously, increased expression of ppGalNAc-T3 was reported to be associated with the progression of esophageal squamous carcinomas (Ishikawa et al. 2005) . However, whether any change occurs in antibody epitopes after the expression of these and other ppGalNAc-Ts during tumorigenesis remains unclear. Our results suggest that the O-glycosylation of MUC21 is initiated during the differentiation of esophageal epithelia.
According to a previous report, the expression of Ki-67 antigen, which represents proliferating cells, was observed in basal and parabasal cells, but not suprabasal cells. Additionally, poorly differentiated squamous cell carcinoma showed high levels of Ki-67 antigen expression (Seery and Watt 2000) . In the skin epithelia, the extension of carbohydrate chains was observed with epithelial cells in parallel with the differentiation of keratinocytes (Brabec et al. 1980; Zieske and Bernstein 1982) . Basal and parabasal cells constitute the stem cell and amplifying cell compartment, while suprabasal cells, which can no longer divide, are undergoing terminal differentiation of the skin. A similar alteration of glycosylation appears to be taking place in esophageal epithelia with MUC21 as a scaffold.
In summary, we prepared mAbs that recognize differentially glycosylated MUC21. These antibodies were capable of distinguishing MUC21-glycoforms in different layers of esophageal epithelia and esophageal squamous carcinomas. Further studies on the regulation and unique functions of MUC21 glycoforms may lead to a novel strategy for the diagnosis and treatment of esophageal squamous carcinomas.
Materials and methods
Cells and cell cultures HEK293 cells were obtained from the American Type Culture Collections and grown in high-glucose Dulbecco's Modified Eagle Medium (Nissui, Tokyo, Japan). Human myeloid leukemia K562 cells were cultured in RPMI 1640 medium (Nissui). CHO cells (CHO-K1 cells) and the glycosylation variants, CHO-Lec2 (Altschuler et al. 2000) obtained from the American Type Culture Collections and ldlD cells (Kingsley et al. 1986 ) provided by Dr M. Krieger were kept in a 1:1 mixture of Dulbecco's modified minimum essential medium (Nissui) and Ham's F12 (Nissui). These media contained 10% fetal calf serum, and cells were cultured at 37°C and 5% CO 2 atmosphere. The mouse myeloma cell line, PAI MUC21 glycoforms revealed by monoclonal antibodies provided by Dr J. Aoki, was propagated in GIT medium (Wako, Tokyo, Japan) supplemented with 5% NCTC109 medium (Gibco, Grand Island, NY), 1% MEM NEAA (Gibco) and 2 mM L-glutamine (Mediatech, Manassas, VA). This formulation is referred as GIT. Newly formed hybridomas were selected in GIT supplemented with HAT mixture (DS Pharma, Suita, Japan) and 10% BM-condimed H1 (Roche, Basel, Switzerland) . This formulation is referred to as BM-HAT-GIT. After selection, the newly formed hybridomas were propagated in GIT supplemented with HT mixture and 10% BM-condimed H1. This formulation is referred as BM-HT-GIT.
Transfection of human MUC21 or mouse Muc21 cDNA
The coding sequence of human MUC21, human MUC21 with a FLAG tag added at the N-terminus and a myc tag added at the C-terminus (N-FLAG-MUC21-C-myc), or MUC21 with a FLAG tag added at N-terminus (N-FLAG-MUC21) were inserted into a mammalian cell expression vector, pcDNA3.1 (Invitrogen, Carlsbad, CA). The pcDNA3.1 plasmid alone was used as a control. K562 cells were transfected with the N-FLAG-MUC21 by electroporation. Transfection of MUC21 or N-FLAG-MUC21-C-myc to HEK293 cells were performed with FuGENE HD (Roche), and transfection of N-FLAG-MUC21 to ldlD, Lec2, and CHO-K1 cells were performed with Lipofectamine 2000 (Invitrogen), according to manufacturer's protocol. After selection with Geneticin (G418 sulfate; Calbiochem, La Jolla, CA), cloning of transfected cells was performed by the limiting dilution method. The coding sequence of mouse Muc21 with a FLAG tag added at the N-terminus (N-FLAG-mouse Muc21) was inserted into the vector, pcDNA3.1 (-) (Invitrogen) or pCAGGS-neo. Transfection of N-FLAG-mouse Muc21-pcDNA3.1 (-) to CHO-K1 cells was performed with DOTAP Liposomal transfection reagent (Roche), and transfection of N-FLAG-mouse Muc21-pCAGGS-neo to Lec2 cells was performed with Lipofectamine 2000 (Invitrogen), according to manufacturer's protocol.
Preparation of mAbs BALB/c mice maintained under specific pathogen-free conditions were immunized intraperitoneally with HEK293 cells transfected with MUC21 (1 × 10 7 cells/mouse) with the Sigma adjuvant system (Sigma-Aldrich, Saint Louis, MO) at weekly intervals. Final boosts of HEK293 cells transfected with MUC21 (1 × 10 7 cells/mouse) were given intravenously 3 days prior to fusion. The use and the care of the mice were performed in accordance with the procedures approved by the life science committee of the University of Tokyo. The spleens were harvested aseptically and homogenized in GIT. Splenocytes and mouse myeloma cells, PAI, were combined at a 5:1 ratio and fused with polyethylene glycol (50% solution). Cell suspensions were incubated with BM-HAT-GIT medium for 5 days at 37°C, 5% CO 2 atmosphere to obtain hybridomas. The supernatants were screened by ELISA using K562 cells transfected with N-FLAG-MUC21 and purified MUC21 prepared from HEK293 cells transfected with N-FLAG-MUC21-C-myc. Cloning of hybridoma cells were performed by the limiting dilution method. Seven clones of hybridoma cells were obtained, and designated as heM21A-G. The isotype of these mAbs were determined by the ELISA using goat antibodies specific for mouse immunoglobulin isotypes (Southern Biotechnology Associates, AL).
ELISA with K562 cells transfected with N-FLAG-MUC21 K562 cells, mock transfected or transfected with N-FLAG-MUC21, in phosphate-buffered saline (PBS) were added to 96-well round plates and blocked with 2% bovine serum albumin (BSA)/PBS for 10 min on ice. The plates were centrifuged at 4000 rpm for 1 min and washed with PBS three times. First, Abs (mouse serum, hybridoma culture supernatant, anti-FLAG-M2 mAb (Sigma-aldrich), and mouse IgG (Invitrogen)) were added to the plates and incubated for 1 h on ice. The plates were then centrifuged and washed three times with PBS. Horse radish peroxidase (HRP)-labeled goat anti-mouse IgG + A + M (H + L) (Invitrogen) (100 μL/well, diluted by 1/1000 in 2% BSA/PBS) was added and incubated for 1 h on ice. The plates were then centrifuged, washed three times with PBS, and incubated with 2,2′-azino-bis [3-ethylbenzothiazoline-6-sulfonate] (ABTS) (Wako) (100 μL/ well of 1 mM ABTS with 1 μL/mL 30% H 2 O 2 ) or tetramethyl benzidine (Sigma-Aldrich) (100 μL/well of 0.1 mg/mL with 0.2 μL/mL 30% H 2 O 2 ). After 15-30 min incubation, the absorbance at 405 nm was measured.
ELISA with purified MUC21 MUC21 ( purified from the lysates of HEK293 cells transfected with N-FLAG-MUC21-C-myc, using anti-FLAG-M2 agarose; Sigma-Aldrich) was added to 96 well plates (3.5 μg/ mL in PBS, 100 μL/well), which were then sealed and incubated overnight at 4°C. The plates were then blocked with 1/5 diluted immunoblock (DS Pharma) for 45 min at room temperature and washed with PBS containing 0.1% Tween-20 (PBST). Then, the primary Abs (mouse serum, hybridoma culture supernatant, anti-FLAG-M2 mAb, and mouse IgG (Invitrogen)) were added and incubated for 1 h at room temperature. Plates were washed three times with PBST, and HRP-goat anti-mouse IgG + A + M (1/1000 diluted with 1/20 immunoblock, 100 μL/well) was added and incubated for 1 h at room temperature. Plates were washed three times, and incubated with ABTS (100 μL/well 1mM ABTS with 1 μL/ mL 30% H 2 O 2 ). After incubation for 15 min, the absorbance at 405 nm was measured.
Flowcytometric analysis
Cells were detached from cell culture plates by the addition of 0.02% ethylenediaminetetraacetic acid (EDTA) in PBS for 5 min, and stained with the following mAbs: anti-FLAG-M2 and mAb heM21A-G in the combination with fluorescein isothiocyanate-labeled goat anti-mouse IgG (Invitrogen). Analysis was performed on an Epics Coulter XL flow cytometer (Beckmann Coulter, Irvine, CA) to determine the level of antibody reactivity. Data were analyzed using FlowJo software (Tree Star, Ashland, OR).
Immunoprecipitation and Western/lectin blotting analysis Cells were lysed in lysis buffer (10 mM Tris pH 7.5, 0.25 M sucrose, 0.25 mM CaCl 2 , 2 mM EDTA, 0.5% NP-40) containing 1% (vol/vol) protease inhibitor cocktail (Merck, Darmstadt, Germany). Anti-FLAG-M2 agarose was added to cell lysates, and the samples were rotated at 4°C for 2 h. After washing with PBS, the agarose was boiled with sample buffer containing 2-mercaptoethanol for 5 min, and the supernatant was separated by SDS gel electrophoresis on a 6% polyacrylamide gel. Protein was transferred from gel onto a polyvinylidene fluoride membrane (Millipore, Billerica, MA) with a semi-dry transfer cell. Nonspecific protein binding was blocked by incubation with 3% BSA in PBS overnight at 4°C. The membrane was incubated with primary antibodies (hybridoma culture supernatants), biotin-conjugated VVA-B4 (0.5 µg/mL; Sigma-Aldrich), or biotin-conjugated PNA (0.5 µg/mL; Seikagaku, Tokyo, Japan) for 2 h at room temperature. After washing with PBST, the membrane was incubated with HRP-conjugated secondary antibodies or HRP-conjugated streptavidin. The blots were visualized using solutions of luminol chemiluminescence reagents, and detected by ImageQuant Las4010 (GE Healthcare, Buckinghamshire, UK).
Immunohistochemical staining of malignant esophagus by hybridoma culture supernatants Surgical specimens were obtained at the National Hospital Organization Osaka National Hospital. Tissues were preserved in 10% buffered formalin, embedded in paraffin, serially sectioned, mounted on silane-coated slides, and deparaffinized. The slides were immersed for 30 min in 1% hydrogen peroxide in PBS to inactivate endogenous peroxidase. After washing 3 times with PBS for 5 min, the sections were incubated with 2% normal goat serum (NGS) and 3% BSA/PBS containing avidin (Vector, Burlingame, CA), to block nonspecific antibody binding, for 30 min at room temperature in a humidified chamber. The slides were then reacted with hybridoma culture supernatant with biotin (Vector) overnight at 4°C, or incubated with 2% NGS-3% BSA/PBS containing biotin (Vector) followed by the reaction with biotinconjugated VVA-B4 (10 μg/mL; Sigma-Aldrich) for 30 min at room temperature. After washing with PBS, biotin conjugated goat anti-mouse IgGAM (Invitrogen) was added to the sections stained with mAbs at a 1:200 dilution in 2% NGS-3% BSA/PBS as the second antibody. The binding of mAbs and VVA-B4 was visualized by HRP-conjugated streptavidin at 1:100 dilutions in 2% NGS-3% BSA/PBS, following incubation with diethylaminobenzidine (Vector). Counterstaining with hematoxylin was performed after incubation with diethylaminobenzidine.
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